Komal Jhaveri

TL;DR: An increased number of alterations in genes involved in the mitogen-activated protein kinase (MAPK) pathway and in the estrogen receptor transcriptional machinery were identified in breast cancers exposed to hormonal therapy and associated with a shorter duration of response to subsequent hormonal therapies.

TL;DR: This study demonstrates how a molecularly driven clinical trial can be used to refine the biological understanding of both characterized and new genomic alterations with potential broad applicability for advancing the paradigm of genome-driven oncology.

TL;DR: This review summarizes the current status of both first and second generation HSP90 inhibitors based on their chemical classification and stage of clinical development and discusses the pharmacodynamic assays currently implemented in clinic as well as other novel strategies aimed at enhancing the effectiveness of Hsp90 inhibitors.

TL;DR: Preliminary analysis of clinical trial data suggests that breast cancers with double mutations are more responsive to PI3K inhibitors than those with a single mutation, and PIK3CA mutational status could help identify the breast cancer patients most likely to benefit from these drugs.

TL;DR: In this article, the authors highlight the current status of the second-generation HSP90 inhibitors in clinical development and highlight the lessons learned from the completed clinical trials of first-and secondgeneration inhibitors and describe various assays attempting to serve for a more rational implementation of these agents to cancer treatment.